
  
    
      
        Introduction_NNP
        As_RB many_JJ as_IN 30_CD %_NN of_IN patients_NNS with_IN breast_NN cancer_NN who_WP have_VBP
        undergone_VBN curative_JJ surgery_NN and_CC show_VB no_DT evidence_NN of_IN
        locoregional_NN or_CC distant_JJ disease_NN still_RB have_VBP recurrent_JJ
        disease_NN over_IN 5_CD -_: 10_CD years_NNS [_NN 1_CD 2_CD ]_NN ._. Some_DT of_IN these_DT treatment_NN
        failures_NNS may_MD be_VB attributed_VBN to_TO residual_JJ disease_NN in_IN the_DT
        breast_NN or_CC axillary_JJ lymph_NN nodes_NNS [_NN 3_CD ]_NN ._. The_DT limitation_NN of_IN
        routine_JJ histopathologic_JJ examination_NN of_IN the_DT tumor_NN margins_NNS
        and_CC the_DT dissected_VBN lymph_NN node_NN specimen_NN is_VBZ well_RB known_VBN [_NN 4_CD ]_NN ._.
        Contemporary_NNP methods_NNS of_IN detection_NN ,_, including_VBG computed_JJ
        tomography_NN ,_, magnetic_JJ resonance_NN imaging_NN ,_, bone_NN scintigraphy_NN
        and_CC flow_NN cytometry_NN ,_, all_DT have_VBP limited_JJ sensitivity_NN and_CC
        specificity_NN [_NN 5_CD 6_CD ]_NN ._. Micrometastases_NNP can_MD be_VB found_VBN by_IN
        immunohistochemistry_NN or_CC polymerase_NN chain_NN reaction_NN in_IN 10_CD -_: 30_CD %_NN
        of_IN the_DT patients_NNS previously_RB deemed_VBN free_JJ of_IN disease_NN by_IN
        conventional_JJ histological_JJ methods_NNS [_NN 7_CD 8_CD ]_NN ._. The_DT prognostic_JJ
        importance_NN of_IN micrometastases_NNS found_VBD with_IN these_DT sensitive_JJ
        methods_NNS are_VBP now_RB being_VBG evaluated_VBN [_NN 9_CD 10_CD 11_CD ]_NN ._.
        Hepatocyte_NNP growth_NN factor_NN /_NN scatter_NN factor_NN (_( HGF_NNP /_NN SF_NNP )_) is_VBZ a_DT
        paracrine_NN factor_NN produced_VBN primarily_RB by_IN mesenchymal_NN cells_NNS ._.
        HGF_NNP /_NN SF_NNP induces_VBZ mitogenic_JJ and_CC morphogenic_JJ changes_NNS ,_, including_VBG
        rapid_JJ membrane_NN ruffling_VBG ,_, formation_NN of_IN microspikes_NNS ,_, and_CC
        increased_VBD cellular_JJ motility_NN [_NN 12_CD 13_CD ]_NN ._. The_DT diverse_JJ
        biological_JJ effects_NNS of_IN HGF_NNP /_NN SF_NNP are_VBP all_DT mediated_JJ by_IN Met_NNP ,_, which_WDT
        is_VBZ preferentially_RB expressed_VBN on_IN epithelial_NN cells_NNS [_NN 14_CD ]_NN ._. 
        In_IN vivo_NN this_DT receptor-ligand_JJ pair_NN is_VBZ
        essential_JJ for_IN normal_JJ embryonic_JJ development_NN [_NN 15_CD 16_CD ]_NN ._.
        Whereas_IN Met_NNP signaling_VBG clearly_RB has_VBZ a_DT role_NN in_IN normal_JJ cellular_JJ
        processes_NNS ,_, this_DT signaling_VBG pathway_NN has_VBZ also_RB been_VBN implicated_VBN
        in_IN tumor_NN development_NN and_CC progression_NN ._. Met_NNP signaling_VBG can_MD
        increase_VB tumorigenicity_NN ,_, induce_VB cell_NN motility_NN ,_, and_CC enhance_VB
        invasiveness_NNS 
        in_IN vitro_NN and_CC metastasis_NNS 
        in_IN vivo_NN [_NN 14_CD 17_CD 18_CD 19_CD 20_CD ]_NN ._. In_IN
        addition_NN ,_, Met_NNP signaling_VBG can_MD increase_VB the_DT production_NN of_IN
        protease_NN and_CC urokinase_NN ,_, which_WDT are_VBP associated_VBN with_IN
        extracellular_NN matrix_NN /_NN basal_NN membrane_NN degradation_NN and_CC are_VBP
        important_JJ for_IN metastasis_NNS [_NN 14_CD 19_CD ]_NN ._.
        Operations_NNP for_IN breast_NN cancer_NN include_VBP either_CC mastectomy_NN
        or_CC breast-conserving_JJ surgery_NN ,_, consisting_VBG of_IN wide_JJ local_JJ
        excision_NN of_IN the_DT tumor_NN with_IN margins_NNS of_IN intact_JJ breast_NN tissue_NN
        (_( '_POS lumpectomy_NN '_'' )_) and_CC axillary_JJ lymph_NN node_NN dissection_NN ._. Drains_NNP
        are_VBP inserted_VBN in_IN the_DT dissected_VBN axilla_NN in_IN most_JJS of_IN these_DT
        operations_NNS ,_, to_TO avoid_VB the_DT accumulation_NN of_IN lymphatic_JJ fluid_NN ._.
        The_DT goals_NNS of_IN this_DT study_NN were_VBD to_TO examine_VB whether_IN Met_NNP can_MD be_VB
        detected_VBN by_IN reverse_NN transcriptase-polymerase_JJ chain_NN reaction_NN
        (_( RT-PCR_NNP )_) in_IN the_DT axillary_JJ drainage_NN from_IN patients_NNS who_WP have_VBP
        undergone_VBN conservative_JJ operations_NNS for_IN breast_NN cancer_NN ,_, and_CC to_TO
        assess_VB the_DT correlations_NNS between_IN the_DT mRNA_NN expression_NN of_IN Met_NNP
        in_IN the_DT collected_VBN fluid_JJ and_CC prognostic_JJ factors_NNS of_IN breast_NN
        cancer_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Patients_NNS and_CC operations_NNS
          Thirty-one_NNP consecutive_JJ women_NNS with_IN invasive_JJ ductal_NN
          carcinoma_NN of_IN the_DT breast_NN ,_, who_WP were_VBD suitable_JJ for_IN
          breast-conserving_JJ treatment_NN ,_, were_VBD studied_VBN ._. We_PRP included_VBD
          only_RB patients_NNS who_WP underwent_VBD conserving_VBG breast_NN surgery_NN so_IN
          that_IN we_PRP could_MD evaluate_VB the_DT correlations_NNS of_IN Met-_NNP HGF_NNP /_NN SF_NNP
          expression_NN with_IN both_DT the_DT tumor_NN margins_NNS and_CC the_DT status_NN of_IN
          the_DT axillary_JJ lymph_NN nodes_NNS ._. The_DT diagnosis_NN of_IN cancer_NN was_VBD
          established_VBN by_IN needle_NN core_NN biopsy_NN (_( '_POS Trucut_NNP '_POS )_) ,_, which_WDT was_VBD
          performed_VBN 2_CD weeks_NNS before_IN the_DT operation_NN ._. All_DT patients_NNS
          underwent_VBD wide_JJ local_JJ excision_NN and_CC axillary_JJ lymph_NN node_NN
          dissection_NN by_IN the_DT same_JJ team_NN ._. Non-palpable_NNP tumors_NNS were_VBD
          localized_VBN by_IN mammography_NN before_IN surgery_NN by_IN wire_NN
          insertion_NN ._. During_IN operations_NNS a_DT wide_JJ resection_NN around_IN the_DT
          wire_NN was_VBD performed_VBN ,_, followed_VBN by_IN mammographic_JJ confirmation_NN
          of_IN complete_JJ resection_NN of_IN the_DT tumors_NNS ._. The_DT axillary_JJ
          dissection_NN was_VBD performed_VBN with_IN a_DT separate_JJ incision_NN ,_, and_CC
          level_VB I_PRP and_CC II_NNP axillary_JJ lymph_NN nodes_NNS were_VBD removed_VBN ._. The_DT
          breast_NN incisions_NNS were_VBD closed_VBN without_IN drainage_NN ,_, and_CC all_DT
          axillae_NN were_VBD drained_VBN postoperatively_RB by_IN closed_JJ vacuum_NN
          drains_VBZ (_( ch-_NN 14_CD ;_: Biometrix_NNP )_) ._. The_DT output_NN of_IN the_DT drain_NN was_VBD
          collected_VBN and_CC measured_VBD every_DT 24_CD hours_NNS ;_: the_DT drains_VBZ were_VBD
          removed_VBN when_WRB the_DT output_NN was_VBD less_JJR than_IN 25_CD ml_NN per_IN 24_CD h_NN ._. The_DT
          presence_NN of_IN Met-_NNP HGF_NNP /_NN SF_NNP and_CC β-actin_JJ were_VBD assessed_VBN in_IN the_DT
          fluid_NN ,_, which_WDT was_VBD collected_VBN during_IN the_DT second_JJ
          postoperative_JJ day_NN because_IN during_IN the_DT first_JJ 24_CD hours_NNS it_PRP
          might_MD contain_VB many_JJ erythrocytes_NNS and_CC debris_NN ._.
        
        
          Pathological_NNP examinations_NNS
          The_DT resected_JJ specimen_NN was_VBD covered_VBN circumferentially_RB by_IN
          black_JJ Indian_JJ ink_NN and_CC Bouins_NNP solution_NN and_CC then_RB was_VBD sliced_JJ
          into_IN 5_CD mm_NN slices_NNS ._. Each_DT slice_NN was_VBD evaluated_VBN
          macroscopically_RB for_IN the_DT presence_NN of_IN tumor_NN and_CC its_PRP$
          distance_NN from_IN the_DT margins_NNS of_IN the_DT specimen_NN ._. All_DT slices_NNS
          involved_VBN with_IN tumor_NN were_VBD paraffin_NN embedded_VBN ,_, sliced_JJ again_RB
          into_IN 4_CD μm_NN slides_NNS ,_, and_CC stained_JJ with_IN hematoxylin-eosin_JJ ._.
          Microscopical_NNP evaluation_NN was_VBD performed_VBN by_IN one_CD pathologist_NN
          for_IN margin_NN involvement_NN ,_, tumor_NN type_NN ,_, size_NN ,_, grade_NN ,_,
          capillary_JJ or_CC lymphatic_JJ invasion_NN ,_, and_CC the_DT distance_NN from_IN
          the_DT margins_NNS ._. All_DT axillary_JJ lymph_NN nodes_NNS were_VBD paraffin_NN
          embedded_VBN ,_, sliced_JJ into_IN 4_CD μm_NN slides_NNS and_CC assessed_VBN for_IN the_DT
          presence_NN of_IN micrometastases_NNS ._.
        
        
          Receptor_NNP assays_NNS
          Estrogen_NNP receptor_NN (_( ER_NNP )_) and_CC progesterone_NN receptor_NN (_( PR_NNP )_)
          were_VBD assessed_VBN in_IN the_DT tumor_NN by_IN immunohistochemical_JJ assay_NN
          with_IN mouse_NN monoclonal_NN antibodies_NNS (_( NCL-ER-_NNP 6_CD F_NN 11_CD and_CC
          NCL-PGR-_NNP 312_CD )_) in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS
          instruction_NN (_( Novocastra_NNP Laboratories_NNPS )_) ._. We_PRP used_VBD the_NNP '_POS quick_JJ
          score_NN '_'' ,_, a_DT simple_JJ combination_NN of_IN the_DT proportion_NN of_IN cells_NNS
          staining_VBG plus_CC a_DT measure_NN of_IN intensity_NN of_IN staining_VBG [_NN 21_CD ]_NN ._.
          A_DT cut-off_JJ value_NN of_IN 2_CD or_CC more_JJR was_VBD taken_VBN as_IN negative_JJ for_IN ER_NNP
          or_CC PR_NNP ._.
        
        
          RT-PCR_NNP assays_NNS
          Total_NNP RNA_NNP was_VBD extracted_VBN from_IN axillary_JJ lymphatic_JJ fluid_NN
          with_IN the_DT Tri_NNP Reagent_NNP procedure_NN ,_, in_IN accordance_NN with_IN the_DT
          manufacturer_NN 's_POS instruction_NN (_( Sigma_NNP )_) ._. Reverse_VBP transcription_NN
          was_VBD performed_VBN with_IN 1_CD -_: 2_CD μg_NN of_IN total_JJ RNA_NNP ._. The_DT first_JJ strand_NN
          of_IN cDNA_NN was_VBD generated_VBN with_IN 0_CD ._. 5_CD μg_NN of_IN (_( dT_NN )_) 
          15_CD primer_NN (_( Gibco-_NNP BRL_NNP )_) using_VBG 200_CD units_NNS
          of_IN subscripts_NNS II_NNP RNAse-H-reverse_NNP transcriptase_NN
          (_( Gibco-_NNP BRL_NNP )_) ._. This_DT was_VBD incubated_JJ for_IN 50_CD min_NN at_IN 42_CD °_NN C_NNP ,_,
          followed_VBN by_IN inactivation_NN for_IN 15_CD min_NN at_IN 70_CD °_NN C_NNP ._. To_TO detect_VB
          Met_NNP transcript_NN ,_, PCR_NNP was_VBD performed_VBN on_IN 3_CD μl_NN of_IN cDNA_NN with_IN
          MP_NNP 1_CD primer_NN (_( 5_CD '_POS -_: GGAATCGAGCTGCGAGA-_NNP 3_CD '_POS )_) and_CC MP_NNP 2_CD primer_NN
          (_( 5_CD '_POS -_: TCCAACATGCAGTTTCTTGC-_NNP 3_CD '_POS )_) ._. To_TO detect_VB β-actin_JJ
          transcript_NN ,_, PCR_NNP was_VBD performed_VBN on_IN 3_CD μl_NN of_IN cDNA_NN with_IN MP_NNP 1_CD
          primer_NN (_( 5_CD '_POS -_: CTCTTCCAGCCTTCCTTCCT-_NNP 3_CD '_POS )_) and_CC MP_NNP 2_CD primer_NN
          (_( 5_CD '_POS -_: AGCACTGTGTTGGCGTACAG-_NNP 3_CD '_POS )_) ._. Cycling_NNP conditions_NNS
          consisted_VBD of_IN 35_CD cycles_NNS with_IN denaturation_NN steps_NNS at_IN 94_CD °_NN C_NNP
          for_IN 30_CD s_VBZ ,_, hybridization_NN steps_NNS at_IN 55_CD °_NN C_NNP for_IN 30_CD s_VBZ and_CC an_DT
          extension_NN step_NN at_IN 72_CD °_NN C_NNP for_IN 1_CD min_NN ._. The_DT β-actin_JJ and_CC c-_NN Met_NNP
          RT-PCRs_NNP were_VBD performed_VBN simultaneously_RB ,_, under_IN the_DT same_JJ
          conditions_NNS ._. The_DT limit_NN of_IN sensitivity_NN of_IN the_DT RT-PCR_NNP system_NN
          for_IN Met_NNP was_VBD 1_CD pg_NN of_IN total_JJ RNA_NNP ._.
        
        
          Immunohistochemical_NNP analyses_NNS
          Staining_NNP was_VBD performed_VBN with_IN an_DT antibody_NN against_IN
          hepatocyte_NN growth_NN factor-α_JJ receptor_NN (_( HGFα-R_NNP ;_: H-_NNP 145_CD ;_: Santa_NNP
          Cruz_NNP Biotechnology_NNP ,_, Santa_NNP Cruz_NNP ,_, California_NNP ,_, USA_NNP )_) ._.
          Sections_NNP (_( 5_CD μm_NN )_) mounted_VBD on_IN Super_NNP Frost_NNP /_NN plus_CC glass_NN (_( Menzel_NNP
          and_CC Claser_NNP ,_, both_DT in_IN Braunschweig_NNP ,_, Germany_NNP )_) ,_, were_VBD
          processed_VBN by_IN a_DT labelled_JJ streptavidin-biotin_JJ method_NN with_IN a_DT
          Histostain_NNP Plus_NNP kit_NN (_( Zymed_NNP ,_, San_NNP Francisco_NNP ,_, California_NNP ,_,
          USA_NNP )_) ._. Heat-induced_NNP antigen_NN retrieval_NN was_VBD performed_VBN by_IN
          temperature-controlled_JJ microwave_NN treatment_NN with_IN an_DT H_NNP 2800_CD
          model_NN processor_NN (_( Energy_NNP Beam_NNP Sciences_NNPS Inc_NNP ,_, Agawan_NNP ,_,
          Massachusetts_NNP ,_, USA_NNP )_) for_IN 12_CD min_NN in_IN 10_CD mM_NN citrate_NN buffer_NN ,_,
          pH_NN 6_CD ._. 0_CD ,_, at_IN 97_CD °_NN C_NNP ._. The_DT sections_NNS were_VBD treated_VBN for_IN 5_CD min_NN with_IN
          3_CD %_NN H_NNP 
          2_CD O_NNP 
          2_CD ,_, followed_VBN by_IN a_DT 10_CD min_NN incubation_NN
          with_IN the_DT universal_JJ blocker_NN ,_, Cas-block_NNP (_( Zymed_NNP )_) ._. The_DT
          sections_NNS were_VBD incubated_JJ for_IN 32_CD min_NN with_IN 1_CD :_: 20_CD diluted_VBN
          HGFα-R_NNP antibody_NN ._. A_DT biotinylated_JJ second_JJ antibody_NN was_VBD
          applied_VBN for_IN 10_CD min_NN ,_, followed_VBN by_IN incubation_NN with_IN
          horseradish_NN peroxidase-conjugated_JJ streptavidin_NN for_IN 10_CD
          min_NN ._. The_DT slides_NNS were_VBD washed_VBN with_IN Optimax_NNP wash_VB buffer_NN
          (_( BioGenex_NNP ,_, San_NNP Ramon_NNP ,_, California_NNP ,_, USA_NNP )_) after_IN each_DT
          incubation_NN ._. The_DT immunoreaction_NN was_VBD revealed_VBN by_IN a_DT
          horseradish_NN peroxidase-based_JJ chromogen_NN ._. The_DT sections_NNS were_VBD
          then_RB counterstained_JJ and_CC cleared_VBD in_IN xylene_NN ._. Controlled_NNP
          staining_VBG was_VBD performed_VBN with_IN human_JJ liver_NN tissue_NN ._. The_DT
          presence_NN of_IN brown_JJ (_( diaminobenzidine_NN )_) staining_VBG of_IN the_DT cell_NN
          membranes_NNS of_IN tumor_NN cells_NNS was_VBD interpreted_VBN as_IN positive_JJ
          reactivity_NN ._.
        
        
          Control_NN group_NN
          To_TO verify_VB that_IN in_IN normal_JJ persons_NNS there_RB is_VBZ no_DT Met_NNP in_IN
          the_DT axilla_NN we_PRP examined_VBD the_DT axillary_JJ drainage_NN in_IN 20_CD
          patients_NNS with_IN malignant_JJ melanoma_NN who_WP were_VBD found_VBN to_TO have_VB
          negative_JJ axillary_JJ sentinel_NN lymph_NN node_NN ._. The_DT lesions_NNS were_VBD
          located_VBN in_IN the_DT upper_JJ limbs_NNS ,_, and_CC the_DT lymph_NN node_NN basins_NNS
          were_VBD found_VBN to_TO be_VB in_IN the_DT axilla_NN ._. Sentinel_NNP lymph_NN nodes_NNS were_VBD
          found_VBN in_IN all_PDT these_DT patients_NNS and_CC none_NN was_VBD involved_VBN with_IN
          melanoma_NN in_IN frozen_VBN sections_NNS or_CC in_IN paraffin-embedded_JJ and_CC
          stained_JJ slices_NNS ._.
        
        
          Statistical_NNP evaluation_NN
          Correlations_NNP between_IN the_DT various_JJ clinicopathological_JJ
          parameters_NNS and_CC RT-PCR_NNP assays_NNS in_IN lymphatic_JJ fluid_NN were_VBD
          analyzed_VBN by_IN the_DT χ_NN 2_CD test_NN (_( 
          P_NN <_NN 0_CD ._. 05_CD )_) ._.
        
      
      
        Results_NNS
        Thirty-one_NNP consecutive_JJ female_JJ patients_NNS who_WP underwent_VBD
        breast-conserving_JJ surgery_NN for_IN operable_JJ invasive_JJ duct_NN
        carcinoma_NN of_IN the_DT breast_NN between_IN 1_CD January_NNP and_CC 30_CD June_NNP 2000_CD
        were_VBD included_VBN ._. Patients_NNS with_IN tumors_NNS that_WDT invaded_VBD the_DT chest_NN
        wall_NN or_CC skin_NN ,_, or_CC with_IN inflammatory_JJ carcinoma_NN ,_, were_VBD
        excluded_VBN ._. The_DT mean_JJ age_NN was_VBD 58_CD ±_NN 16_CD years_NNS ._. Twenty-three_NNP
        patients_NNS (_( 74_CD ._. 2_LS %_NN )_) underwent_VBD lumpectomy_NN for_IN palpable_JJ masses_NNS ,_,
        and_CC in_IN eight_CD women_NNS (_( 25_CD ._. 8_CD %_NN )_) wire-guided_JJ excision_NN of_IN
        non-palpable_JJ tumors_NNS was_VBD performed_VBN ._. The_DT tumor_NN size_NN was_VBD 0_CD -_: 1_CD
        cm_NN in_IN 10_CD women_NNS (_( 32_CD ._. 2_LS %_NN )_) ,_, 1_CD -_: 2_CD cm_NN in_IN 9_CD (_( 29_CD ._. 0_CD %_NN )_) ,_, 2_CD -_: 5_CD cm_NN in_IN 11_CD
        (_( 35_CD ._. 4_LS %_NN )_) ,_, and_CC larger_JJR than_IN 5_CD cm_NN in_IN 1_CD (_( 3_CD ._. 2_LS %_NN )_) ._. Four_CD patients_NNS
        (_( 12_CD ._. 9_CD %_NN )_) had_VBD grade_NN I_PRP tumors_NNS ,_, 19_CD (_( 61_CD ._. 3_LS %_NN )_) had_VBD grade_NN II_NNP
        lesions_NNS ,_, and_CC grade_NN III_NNP tumors_NNS were_VBD found_VBN in_IN 8_CD (_( 25_CD ._. 8_CD %_NN )_) ._.
        Lymphatic_NNP and_CC capillary_JJ invasion_NN were_VBD noted_VBN in_IN 10_CD (_( 32_CD ._. 2_LS %_NN )_)
        and_CC 11_CD (_( 35_CD ._. 4_LS %_NN )_) patients_NNS ,_, respectively_RB ._. While_IN attempting_VBG to_TO
        achieve_VB free_JJ margins_NNS ,_, five_CD patients_NNS (_( 16_CD ._. 1_LS %_NN )_) had_VBD to_TO undergo_VB
        re-excision_JJ owing_VBG to_TO incomplete_JJ resections_NNS ._. Two_CD of_IN these_DT
        patients_NNS had_VBD wire-guided_JJ excisions_NNS ._.
        The_DT collected_VBN axillary_JJ fluids_NNS were_VBD assessed_VBN by_IN RT-PCR_NNP
        for_IN Met_NNP and_CC β-actin_JJ ._. The_DT β-actin_JJ RT-PCR_NNP served_VBD as_IN positive_JJ
        control_NN and_CC gave_VBD strong_JJ signals_NNS in_IN all_DT cases_NNS ,_, indicating_VBG
        that_IN both_DT RNA_NNP preparation_NN and_CC cDNA_NN synthesis_NN were_VBD
        successful_JJ ._. The_DT RT-PCR_NNP assays_NNS were_VBD positive_JJ for_IN Met_NNP in_IN 23_CD
        (_( 74_CD ._. 2_LS %_NN )_) of_IN the_DT breast_NN cancer_NN patients_NNS (_( Fig_NNP ._. 1_LS )_) ._. In_IN all_DT of_IN
        the_DT patients_NNS in_IN the_DT control_NN group_NN ,_, RT-PCR_NNP gave_VBD positive_JJ
        results_NNS for_IN β-actin_JJ but_CC was_VBD negative_JJ for_IN Met_NNP ._.
        The_DT correlations_NNS between_IN tumor_NN size_NN and_CC the_DT presence_NN of_IN
        Met_NNP in_IN the_DT axillary_JJ fluid_JJ are_VBP shown_VBN in_IN Table_NNP 1_CD ._. Positive_JJ
        RT-PCR_NNP assays_NNS for_IN Met_NNP in_IN the_DT lymphatic_JJ fluids_NNS were_VBD
        associated_VBN with_IN increasing_VBG tumor_NN size_NN ._. Eleven_CD of_IN 19_CD
        patients_NNS (_( 57_CD ._. 9_CD %_NN )_) with_IN T_NN 1_CD tumors_NNS (_( tumor_NN size_NN 0_CD -_: 2_CD cm_NN )_) had_VBD
        positive_JJ Met_NNP in_IN the_DT axillary_JJ fluid_JJ (_( 50_CD %_NN and_CC 66_CD %_NN for_IN tumors_NNS
        0_CD -_: 1_CD and_CC 1_CD -_: 2_CD cm_NN in_IN size_NN respectively_RB )_) ,_, compared_VBN with_IN 12_CD of_IN
        12_CD patients_NNS (_( 100_CD %_NN )_) with_IN T_NN 2_CD and_CC T_NN 3_CD tumors_NNS (_( 
        P_NN <_NN 0_CD ._. 01_CD )_) ._.
        The_DT average_JJ number_NN (_( ±_NN SD_NNP )_) of_IN axillary_JJ lymph_NN nodes_NNS was_VBD 17_CD
        ±_NN 4_CD ,_, and_CC all_DT dissected_VBN nodes_NNS were_VBD examined_VBN for_IN the_DT presence_NN
        of_IN metastases_NNS ._. Twelve_CD patients_NNS (_( 38_CD ._. 7_CD %_NN )_) had_VBD axillary_JJ lymph_NN
        node_NN metastases_NNS as_IN revealed_VBN by_IN hematoxylin-eosin_JJ staining_VBG ._.
        The_DT correlation_NN between_IN metastatic_JJ axillary_JJ lymph_NN node_NN
        involvement_NN and_CC the_DT presence_NN of_IN Met_NNP in_IN the_DT lymphatic_JJ fluid_NN
        is_VBZ shown_VBN in_IN Table_NNP 2_CD ._. All_DT 12_CD patients_NNS with_IN axillary_JJ lymph_NN
        node_NN metastases_NNS had_VBD positive_JJ RT-PCR_NNP assays_NNS for_IN Met_NNP ,_,
        compared_VBN with_IN 57_CD ._. 9_CD %_NN (_( 11_CD of_IN 19_CD )_) positive_JJ assays_NNS for_IN women_NNS
        without_IN lymph_NN node_NN metastases_NNS (_( 
        P_NN <_NN 0_CD ._. 01_CD )_) ._.
        All_DT five_CD patients_NNS with_IN tumor_NN involvement_NN in_IN the_DT margins_NNS
        of_IN the_DT resection_NN had_VBD positive_JJ RT-PCR_NNP assays_NNS for_IN Met_NNP in_IN
        their_PRP$ lymphatic_JJ fluid_NN ,_, compared_VBN with_IN 18_CD of_IN 26_CD positive_JJ
        assays_NNS (_( 69_CD ._. 2_LS %_NN )_) for_IN patients_NNS without_IN involved_VBN margins_NNS (_( 
        P_NN <_NN 0_CD ._. 04_CD )_) ._. The_DT associations_NNS
        between_IN tumor_NN grade_NN ,_, capillary_JJ and_CC lymphatic_JJ invasion_NN ,_, and_CC
        the_DT presence_NN of_IN Met_NNP in_IN the_DT axillary_JJ fluid_JJ are_VBP presented_VBN in_IN
        Table_NNP 3_CD ._. Patients_NNPS with_IN lymphatic_JJ invasion_NN of_IN the_DT tumor_NN were_VBD
        all_DT Met-positive_NNP (_( 10_CD of_IN 10_CD )_) ,_, and_CC patients_NNS without_IN lymphatic_JJ
        invasion_NN had_VBD 61_CD ._. 9_CD %_NN (_( 13_CD of_IN 21_CD )_) positive_JJ assays_NNS for_IN Met_NNP (_( 
        P_NN <_NN 0_CD ._. 02_CD )_) ._. Capillary_NNP invasion_NN of_IN
        the_DT tumor_NN was_VBD also_RB found_VBN to_TO be_VB in_IN correlation_NN with_IN Met_NNP ;_:
        although_IN all_DT 11_CD patients_NNS with_IN capillary_JJ invasion_NN had_VBD
        positive_JJ RT-PCR_NNP assays_NNS for_IN Met_NNP in_IN their_PRP$ axillary_JJ fluid_NN ,_, the_DT
        assays_NNS were_VBD positive_JJ in_IN only_RB 60_CD %_NN (_( 12_CD of_IN 20_CD )_) patients_NNS
        without_IN capillary_JJ invasion_NN (_( 
        P_NN <_NN 0_CD ._. 02_CD )_) ._. The_DT presence_NN of_IN Met_NNP in_IN
        the_DT axillary_JJ drainage_NN was_VBD also_RB correlated_JJ with_IN higher_JJR tumor_NN
        grade_NN :_: it_PRP was_VBD found_VBN in_IN 50_CD %_NN of_IN grade_NN I_PRP tumors_NNS ,_, compared_VBN with_IN
        87_CD ._. 5_LS %_NN of_IN grade_NN III_NNP lesions_NNS (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) ._.
        The_DT correlations_NNS between_IN the_DT ER_NNP and_CC PR_NNP status_NN and_CC RT-PCR_NNP
        assays_NNS for_IN Met_NNP in_IN the_DT axillary_JJ fluid_JJ are_VBP shown_VBN in_IN Table_NNP 4_CD ._.
        Seventeen_CD patients_NNS had_VBD ER-negative_NNP tumors_NNS ,_, and_CC 16_CD (_( 94_CD ._. 1_LS %_NN )_)
        of_IN these_DT had_VBN Met-positive_NNP assays_NNS in_IN the_DT axillary_JJ fluid_NN ._. In_IN
        seven_CD (_( 87_CD ._. 5_LS %_NN )_) of_IN the_DT eight_CD patients_NNS with_IN Met-negative_NNP
        assays_NNS the_DT ER_NNP were_VBD positive_JJ ._. Similarly_RB ,_, 21_CD patients_NNS had_VBD
        PR-negative_NNP tumors_NNS ,_, and_CC 20_CD (_( 95_CD ._. 2_LS %_NN )_) of_IN these_DT were_VBD positive_JJ
        for_IN Met_NNP ._. PR-positive_NNP tumors_NNS were_VBD found_VBN in_IN seven_CD of_IN eight_CD
        patients_NNS (_( 87_CD ._. 5_LS %_NN )_) in_IN whom_WP assays_NNS for_IN Met_NNP in_IN the_DT axillary_JJ
        drainage_NN were_VBD negative_JJ ._.
        All_DT the_DT paraffin-embedded_JJ sections_NNS of_IN the_DT resected_JJ
        primary_JJ breast_NN cancers_NNS were_VBD assessed_VBN by_IN
        immunohistochemistry_NN staining_VBG for_IN Met_NNP ._. In_IN 28_CD patients_NNS
        (_( 90_CD ._. 3_LS %_NN )_) the_DT primary_JJ tumor_NN stained_JJ positively_RB for_IN Met_NNP and_CC
        none_NN of_IN the_DT tumors_NNS that_WDT had_VBD negative_JJ staining_VBG had_VBD a_DT
        positive_JJ Met_NNP RT-PCR_NNP assay_NN in_IN the_DT axillary_JJ drainage_NN ._. In_IN
        addition_NN ,_, the_DT patients_NNS with_IN negative_JJ staining_VBG had_VBN no_DT
        involvement_NN of_IN lymph_NN nodes_NNS ._.
      
      
        Discussion_NNP
        HGF_NNP /_NN SF_NNP is_VBZ synthesized_JJ as_IN a_DT pro-_JJ HGF_NNP ,_, and_CC once_RB activated_VBN
        by_IN the_DT HGF_NNP activator_NN (_( HGFA_NNP )_) ,_, the_DT complex_JJ HGF_NNP /_NN SF-Met_NNP affects_VBZ
        numerous_JJ normal_JJ cellular_JJ processes_VBZ [_NN 22_CD ]_NN ._. HGF_NNP /_NN SF-Met_NNP is_VBZ
        also_RB involved_VBN in_IN malignant_JJ transformation_NN ,_, presumably_RB as_IN a_DT
        mediator_NN in_IN interaction_NN between_IN tumor_NN and_CC stroma_NN ,_, which_WDT
        enhances_VBZ tumor_NN progression_NN ,_, and_CC also_RB angiogenesis_NNS [_NN 23_CD 34_CD ]_NN
        ._. In_IN invasive_JJ ductal_NN carcinoma_NN ,_, stronger_JJR expression_NN of_IN
        HGF_NNP /_NN SF_NNP seems_VBZ to_TO be_VB associated_VBN with_IN tubule_NN formation_NN [_NN 25_CD ]_NN
        ._. HGF_NNP /_NN SF_NNP is_VBZ overexpressed_JJ in_IN breast_NN carcinoma_NN 
        in_IN situ_NN and_CC invasive_JJ ductal_NN carcinoma_NN
        in_IN comparison_NN with_IN normal_JJ breast_NN tissue_NN ._. Normal_NNP mammary_JJ
        ducts_NNS within_IN infiltrating_VBG cancer_NN showed_VBD intermediate_JJ levels_NNS
        of_IN HGF_NNP /_NN SF_NNP ._. This_DT finding_VBG suggests_VBZ that_IN the_DT expression_NN of_IN
        these_DT proteins_NNS in_IN breast_NN cancer_NN is_VBZ regulated_VBN by_IN soluble_JJ
        factors_NNS produced_VBN by_IN the_DT tumor_NN cells_NNS [_NN 26_CD 27_CD ]_NN ._. High_NNP levels_NNS
        of_IN expression_NN of_IN HGF_NNP and_CC Met_NNP are_VBP associated_VBN with_IN invasive_JJ
        breast_NN cancer_NN ,_, and_CC might_MD be_VB causally_RB linked_VBN to_TO early_JJ
        recurrences_NNS ,_, metastatic_JJ disease_NN and_CC shortened_VBN survival_NN of_IN
        breast_NN cancer_NN patients_NNS [_NN 28_CD 29_CD ]_NN ._. High_NNP levels_NNS of_IN HGF_NNP /_NN SF_NNP
        detected_VBD within_IN breast_NN tumor_NN extracts_NNS are_VBP correlated_JJ with_IN
        larger_JJR tumor_NN size_NN and_CC shorter_JJR relapse-free_JJ and_CC overall_JJ
        survival_NN compared_VBN with_IN tumors_NNS with_IN low_JJ HGF_NNP /_NN SF_NNP concentration_NN
        [_NN 30_CD ]_NN ._.
        The_DT activation_NN of_IN HGF_NNP /_NN SF_NNP by_IN HGFA_NNP might_MD be_VB modified_VBN by_IN
        the_DT two_CD HGFA_NNP inhibitors_NNS ,_, HAI-_NNP 1_CD and_CC HAI-_NNP 2_CD ._. Highly_NNP invasive_JJ
        breast_NN cancer_NN cells_NNS express_VBP large_JJ amounts_NNS of_IN HGF_NNP and_CC Met_NNP ,_,
        and_CC no_DT HAI-_NNP 1_CD ,_, whereas_IN breast_NN cancer_NN cells_NNS with_IN low_JJ invasive_JJ
        potential_JJ have_VBP low_JJ levels_NNS of_IN HGF_NNP and_CC Met_NNP ,_, and_CC high_JJ levels_NNS
        of_IN HAI-_NNP 1_CD [_NN 22_CD ]_NN ._. In_IN a_DT mouse_NN model_NN system_NN HGF_NNP antagonists_NNS
        suppressed_VBD the_DT conversion_NN of_IN pancreatic_JJ tumors_NNS from_IN
        carcinoma_NN 
        in_IN situ_NN into_IN invasive_JJ cancer_NN [_NN 23_CD ]_NN ._.
        It_PRP seems_VBZ that_DT regulation_NN of_IN the_DT HGF_NNP /_NN SF_NNP stimulation_NN and_CC
        inhibition_NN activities_NNS is_VBZ associated_VBN with_IN the_DT metastatic_JJ
        potential_NN of_IN tumor_NN cells_NNS ,_, and_CC knowing_VBG the_DT status_NN of_IN HGFA_NNP ,_,
        HAI-_NNP 1_CD and_CC HAI-_NNP 2_CD ,_, in_IN addition_NN to_TO Met_NNP ,_, might_MD provide_VB useful_JJ
        information_NN ._.
        HGF_NNP /_NN SF_NNP and_CC Met_NNP have_VBP been_VBN found_VBN in_IN a_DT variety_NN of_IN tumors_NNS [_NN
        31_CD 32_CD 33_CD ]_NN ,_, and_CC in_IN lymph_NN nodes_NNS of_IN patients_NNS with_IN no_DT tumor_NN [_NN
        34_CD ]_NN ,_, but_CC never_RB in_IN the_DT fluid_JJ drained_VBN from_IN the_DT tumor_NN bed_NN or_CC
        the_DT lymph_NN node_NN basin_NN ._. In_IN this_DT study_NN we_PRP evaluated_VBD whether_IN
        Met_NNP can_MD be_VB detected_VBN in_IN the_DT axillary_JJ drainage_NN of_IN breast_NN
        cancer_NN patients_NNS ,_, and_CC the_DT significance_NN of_IN its_PRP$ expression_NN in_IN
        the_DT lymphatic_JJ fluid_NN ._. Studying_NNP the_DT expression_NN of_IN Met_NNP in_IN the_DT
        axillary_JJ fluid_NN is_VBZ a_DT simple_JJ ,_, non-invasive_JJ procedure_NN because_IN
        drains_VBZ are_VBP routinely_RB inserted_VBN during_IN axillary_JJ lymph_NN node_NN
        dissections_NNS ._. The_DT collected_VBN fluid_NN is_VBZ readily_RB available_JJ ,_, and_CC
        RT-PCR_NNP is_VBZ a_DT routine_JJ ,_, short_JJ assay_NN with_IN minimum_JJ
        artefacts_NNS ._.
        The_DT axillary_JJ fluid_NN after_IN breast_NN and_CC axillary_JJ lymph_NN node_NN
        operations_NNS includes_VBZ erythrocytes_NNS ,_, lymphocytes_NNS ,_, epithelial_NN
        cells_NNS and_CC tumor_NN cells_NNS ._. One_CD of_IN the_DT goals_NNS of_IN this_DT work_NN was_VBD to_TO
        examine_VB whether_IN tumor_NN cells_NNS can_MD be_VB detected_VBN in_IN the_DT axillary_JJ
        drainage_NN by_IN RT-PCR_NNP assays_NNS for_IN Met_NNP ._. To_TO determine_VB the_DT source_NN
        of_IN Met_NNP in_IN the_DT axillary_JJ fluid_NN in_IN breast_NN cancer_NN patients_NNS and_CC
        to_TO exclude_VB the_DT possibility_NN that_IN the_DT source_NN was_VBD related_VBN to_TO
        surgical_JJ trauma_NN ,_, we_PRP evaluated_VBD a_DT control_NN group_NN of_IN melanoma_NN
        patients_NNS with_IN negative_JJ axillary_JJ sentinel_NN lymph_NN nodes_NNS ._. In_IN
        none_NN of_IN the_DT control_NN patients_NNS was_VBD the_DT axillary_JJ drainage_NN
        Met-positive_NNP ._. In_IN 28_CD patients_NNS the_DT primary_JJ tumor_NN stained_JJ
        positively_RB for_IN Met_NNP and_CC none_NN of_IN the_DT tumors_NNS that_WDT had_VBD negative_JJ
        immunostaining_VBG had_VBD a_DT positive_JJ Met_NNP RT-PCR_NNP assay_NN in_IN the_DT
        axillary_JJ drainage_NN ._. Thus_RB ,_, it_PRP seems_VBZ likely_JJ that_IN the_DT source_NN of_IN
        Met_NNP in_IN the_DT axillary_JJ fluid_NN in_IN node-negative_JJ breast_NN cancer_NN
        patients_NNS is_VBZ the_DT tumor_NN in_IN the_DT breast_NN ._.
        The_DT results_NNS show_VBP that_IN Met_NNP can_MD be_VB detected_VBN in_IN the_DT
        axillary_JJ drainage_NN ,_, and_CC although_IN the_DT number_NN of_IN patients_NNS was_VBD
        not_RB high_JJ ,_, Met_NNP is_VBZ associated_VBN with_IN unfavorable_JJ prognostic_JJ
        factors_NNS ._. Positive_JJ assays_NNS for_IN Met_NNP are_VBP correlated_JJ with_IN tumor_NN
        size_NN ,_, grade_NN ,_, lymphatic_JJ invasion_NN ,_, tumor_NN involvement_NN of_IN the_DT
        margins_NNS of_IN the_DT resected_JJ specimen_NN ,_, the_DT existence_NN of_IN
        metastases_NNS in_IN the_DT lymph_NN nodes_NNS ,_, and_CC the_DT numbers_NNS of_IN lymph_NN
        nodes_NNS with_IN tumor_NN ._. Met_NNP was_VBD associated_VBN with_IN larger_JJR tumors_NNS ,_,
        and_CC in_IN none_NN of_IN the_DT patients_NNS with_IN tumors_NNS larger_JJR than_IN 2_CD cm_NN
        was_VBD the_DT assay_NN negative_JJ ._. Moreover_RB ,_, Met_NNP was_VBD never_RB negative_JJ in_IN
        patients_NNS with_IN metastatic_JJ carcinoma_NN in_IN the_DT lymph_NN node_NN ._.
        Negative_JJ staining_VBG for_IN ER_NNP and_CC PR_NNP is_VBZ associated_VBN with_IN
        unfavorable_JJ prognosis_NN ,_, and_CC the_DT assays_NNS for_IN Met_NNP in_IN the_DT
        axillary_JJ fluid_NN were_VBD positive_JJ in_IN most_JJS receptor-negative_JJ
        tumors_NNS ._.
        One_PRP could_MD postulate_NN that_IN because_IN Met_NNP was_VBD highly_RB
        correlated_JJ with_IN tumor_NN size_NN ,_, its_PRP$ expression_NN implies_VBZ
        aggressive_JJ behavior_NN of_IN the_DT malignant_JJ processes_NNS ._. The_DT
        significance_NN of_IN HGF_NNP /_NN SF_NNP as_IN a_DT marker_NN of_IN poor_JJ prognosis_NN might_MD
        also_RB be_VB associated_VBN with_IN its_PRP$ effects_NNS on_IN acquired_VBN resistance_NN
        to_TO anti-cancer_JJ drugs_NNS [_NN 35_CD 36_CD ]_NN ._. HGF_NNP /_NN SF_NNP protects_VBZ cancer_NN
        cells_NNS from_IN DNA-damaging_NNP chemotherapy_NN agents_NNS through_IN
        pathways_NNS involving_VBG signaling_VBG from_IN Met_NNP to_TO phosphoinositide_NN
        3_CD -_: kinase_NN and_CC c-_NN Akt_NNP [_NN 29_CD ]_NN ._. Human_NNP breast_NN cancer_NN cells_NNS ,_,
        preincubated_JJ with_IN HGF_NNP /_NN SF_NNP and_CC then_RB exposed_VBN to_TO Adriamycin_NNP ,_,
        exhibit_NN an_DT altered_VBN pattern_NN of_IN gene_NN expression_NN compared_VBN with_IN
        cells_NNS treated_VBN with_IN Adriamycin_NNP alone_RB ._. Cells_NNP treated_VBD with_IN
        HGF_NNP /_NN SF_NNP and_CC Adriamycin_NNP also_RB had_VBD modified_VBN cell_NN line_NN
        regulation_NN and_CC signal_NN transduction_NN that_WDT might_MD suggest_VB
        mechanisms_NNS by_IN which_WDT HGF_NNP /_NN SF_NNP exerts_NNS its_PRP$ protective_JJ activity_NN [_NN
        31_CD ]_NN ._.
        To_TO our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ report_NN of_IN the_DT
        expression_NN of_IN Met_NNP in_IN the_DT axillary_JJ drainage_NN in_IN patients_NNS who_WP
        have_VBP undergone_VBN operations_NNS for_IN breast_NN cancer_NN ._. The_DT results_NNS
        suggest_VBP that_IN the_DT expression_NN of_IN Met_NNP in_IN the_DT axillary_JJ drainage_NN
        might_MD have_VB prognostic_JJ significance_NN ._. More_RBR importantly_RB ,_, its_PRP$
        expression_NN in_IN histologically_RB node-negative_JJ patients_NNS point_VBP
        to_TO the_DT need_NN to_TO search_VB for_IN node_NN micrometastasis_NNS or_CC
        involvement_NN of_IN the_DT excision_NN margins_NNS by_IN tumor_NN ._. Therefore_RB ,_,
        RT-PCR_NNP for_IN Met_NNP in_IN the_DT axillary_JJ fluid_NN of_IN patients_NNS who_WP
        undergo_VBP breast-conserving_JJ surgery_NN for_IN breast_NN cancer_NN could_MD
        influence_VB therapy_NN ._. The_DT results_NNS of_IN this_DT study_NN justify_VB
        prospective_JJ investigation_NN on_IN a_DT larger_JJR scale_NN ,_, and_CC the_DT
        clinical_JJ significance_NN of_IN Met_NNP positivity_NN in_IN the_DT axillary_JJ
        drainage_NN fluid_JJ in_IN breast_NN cancer_NN patients_NNS should_MD be_VB defined_VBN
        by_IN an_DT extended_VBN follow-up_JJ study_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreivations_NNP
        ER_NNP =_SYM estrogen_NN receptor_NN ;_: HGFA_NNP =_SYM hepatocyte_NN growth_NN factor_NN
        activator_NN ;_: HGF_NNP /_NN SF_NNP =_SYM hepatocyte_NN growth_NN factor_NN /_NN scatter_NN
        factor_NN ;_: PR_NNP =_SYM progesterone_NN receptor_NN ;_: RT-PCR_NNP =_SYM reverse_VB
        transcriptase-polymerase_JJ chain_NN reaction_NN ._.
      
    
  
